

1 The utility of quantitative D-Dimer assay as a biomarker in the diagnosis and exclusion of

2 Cerebral Venous Sinus Thrombosis

3

4 Dipesh Soni<sup>1\*</sup>, Ashok Kumar Pannu<sup>1</sup>, Atul Saroch<sup>1</sup>, Vikas Bhatia<sup>2</sup>, Jasmina Ahluwalia<sup>3</sup>,

5 Rajveer Singh<sup>4</sup>, Arihant Jain<sup>1</sup>

6

7 <sup>1</sup> Department of Internal Medicine, PGIMER, Chandigarh, India

8 <sup>2</sup> Department of Radiodiagnosis PGIMER, Chandigarh, India

9 <sup>3</sup> Department of Haematology PGIMER, Chandigarh, India

10 <sup>4</sup> Department of Neurology PGIMER, Chandigarh, India

11

12 \*Corresponding author

13 [ochdipes@gmail.com](mailto:ochdipes@gmail.com) (DS)

14

15

16

17

18

19

20

21

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

## 22 Abstract

23 Thrombotic disorders are characterized by the presence of elevated levels of detectable  
24 fibrin degradation products in the blood. The utility and sensitivity of quantitative D-Dimer  
25 assay to rule out the diagnosis of deep vein thrombosis is well established. We extrapolated  
26 this principle to evaluate the utility of D-Dimer assay in exclusion of cerebral venous sinus  
27 thrombosis (CVST). CVST is an important cause of cerebrovascular accidents in young  
28 patients and the residual neurological deficits can be minimized if correct therapy, i.e.,  
29 anticoagulation is instituted in a timely manner. As advanced imaging modalities that are  
30 required for the diagnosis of CVST might not be readily available everywhere, it is important  
31 to have a sensitive biomarker which can guide clinicians to rule out the diagnosis with a  
32 reasonable confidence. We evaluated the patients admitted at a tertiary care center who  
33 underwent Computed tomography (CT) Venography/Magnetic resonance (MR) Venography  
34 of the brain with the clinical suspicion of CVST. After appropriate exclusion, a quantitative D-  
35 Dimer assay was performed in patients who had CVST on CT/MR Venography and was  
36 compared with those patients who did not. Receiver operating characteristic (ROC) analysis  
37 revealed that quantitative D Dimer had poor diagnostic accuracy for the differentiation of  
38 CVST from non CVST cases (Area under the curve = 0.694), but D-Dimer levels of <300 ng/mL  
39 had a sensitivity of 90% for ruling out the diagnosis of CVST.

40

41

42

43

## 44 Introduction

45 Cerebral venous sinus thrombosis is understood as any thrombotic event taking place in the  
46 intracerebral veins or sinuses. It is an uncommon cause of stroke with nonspecific clinical  
47 presentation, various risk factors, different radiological findings and varied outcomes.  
48 Prompt recognition, early diagnosis and initiation of anticoagulation therapy can  
49 significantly reduce the incidence of acute and long-term complications. [1] Lack of a proper  
50 dedicated CVST registry bereft us of exact incidence & prevalence of CVST, but with the  
51 introduction of sophisticated radiological techniques, the incidence of CVST has increased  
52 in the past few years. Children, younger adults and females of reproductive age group from  
53 low-income countries are the most commonly affected population group. [2] There are no  
54 population-based studies in India, and with limited evidence from hospital based studies, a  
55 varied incidence of CVST seems apparent. Hospital-based series from Northern India in the  
56 late 1970s reported CVST in 4.5/1000 obstetric admissions. [3] In an autopsy series by  
57 Banerjee et al., CVST accounted for almost 10% of all strokes reported in their study. [4] A  
58 closer look at the available data from different case series suggests that the prevalence of  
59 CVST in India is comparable, if not more, than the reported prevalence in the western  
60 countries. The mechanism of neuronal injury in CVST differs significantly from that of the  
61 arterial occlusive diseases. In arterial occlusion, the nutrient and oxygen supply directly get  
62 cut off which leads to subsequent cerebral ischemia and infarction. When the venous  
63 system is occluded, drainage of blood is compromised. Hydrostatic pressure increases in  
64 vessels that were being drained by the now obstructed veins and sinuses, and cerebral  
65 edema develops in the involved territory. If the pressure is not relieved promptly, cerebral  
66 haemorrhage may ensue owing to capillary fragility at elevated pressures. The significant

67 radiological findings that are present in patients of CVST include localized cerebral edema  
68 and areas of hemorrhage. The bleed can also spill out into the nearby subarachnoid space.  
69 [5]

70 The venous drainage of brain is taken care of by two systems, the superficial and the deep  
71 venous systems. The superficial drainage system is highly collateralized and drained into the  
72 Superior sagittal sinus and the Lateral sinus and the diagnosis of occlusion in this drainage  
73 system solely on clinical grounds is an arduous task. The deep venous system is responsible  
74 for draining the basal ganglia, deep white matter tracts towards the vein of Galen. Many  
75 anastomoses have been identified between the two drainage systems; however, the  
76 presence of anastomoses is not consistent and may be absent or poorly developed. (6) Prior  
77 to the era of antibiotics, most cases of CVST were due to infections involving the meninges,  
78 paranasal sinuses, face, ear, head and neck. In today's world, where the threshold for  
79 initiating an antibiotic for a suspected infection is low, infections no more stand on top of  
80 the list as a potential causes of CVST. A person's genetic susceptibility and environmental  
81 triggers push the individual towards developing the procoagulant state and thus, increases  
82 the chances of the individual having a thrombotic phenomenon.[7]

83 Before the advent of sophisticated imaging techniques such as computed tomography(CT)  
84 and magnetic resonance imaging (MRI), CVST was considered by many as a fatal disease that  
85 usually was diagnosed at autopsy. although this problem was significantly overcome by the  
86 introduction of advanced imaging modalities, widespread access and logistics remain a  
87 problem. Given the fact that CVST has a non-specific clinical presentation and examination  
88 findings, evaluating patients at a large volume centre can be challenging. Hence there is a

89 need for a bedside point of care testing/diagnostic scoring for identification and timely  
90 management of CVST. [6]

91 The treatment strategy for CVST aims to reduce the symptoms of raised intracranial  
92 pressure secondary to venostasis, along with the management of seizures and the deficits  
93 that may come into the picture with development of cerebral edema and infarction.  
94 Anticoagulation is the cornerstone of treatment and is the standard of practice unless any  
95 contraindication to its use is present. Surgical and endovascular techniques are employed in  
96 situations where anticoagulants are ineffective. [7] Long term complications observed at  
97 follow up of these patients include extensive venous collateral formation, Dural AV fistula  
98 formation, raised ICP, which can cause herniation and permanent neurological deficits such  
99 as blindness or incoordination. [8] This study aims to evaluate the utility of quantitative D  
100 Dimer assay in the diagnosis and exclusion of CVST and to devise a clinical decision rule and  
101 for the diagnosis if CVST.

102

## 103 **Methods**

104

### 105 **Study design**

106 This is a hospital based, prospective, observational study that was carried out at tertiary  
107 care centre in northern India. The study was carried out for a period of 17 months between  
108 June 2020 to December 2021.

109 **Inclusion criteria:**

- 110 1. Adult patients (age > 18 years) with suspected cerebral venous thrombosis  
111 Undergoing CT Venography (CTV) or angiography (CTA)/Magnetic resonance  
112 Venography (MRV) or angiography(MRA) .  
113 2. Patient with symptom duration less than seven days.

114 **Exclusion criteria:**

- 115 1. Patients not giving consent for evaluation  
116 2. Patients with symptom duration more than seven days.  
117 3. Patients with proven/known thromboembolic disease (e.g., Deep vein thrombosis,  
118 pulmonary embolism) within the past four weeks.  
119 4. Patients with Disseminated intravascular coagulation

120 Patients presenting with clinical features that raise the suspicion for cerebral venous sinus  
121 thrombosis, namely, 1. headache, 2. focal neurological deficits in the form of hearing  
122 disturbances, visual disturbances, motor and sensory deficits, 3. altered sensorium, 4.  
123 Seizures were planned for further diagnostic evaluation using CTV/CTA or MRV/MRA. At the  
124 end of the aforementioned investigation, the patients were divided into two groups, those  
125 that had features of CVST on radiological imaging (positive cases) and those who did not  
126 have any imaging findings suggestive of CVST (negative cases). A blood sample of 2.7 ml in a  
127 3.2% sodium citrate vial was collected for quantitative D dimer levels. The blood sample was  
128 drawn before the patient injected with IV contrast, thus, any possible interference that may  
129 be because of the contrast was avoided. D Dimer estimation was done using the  
130 commercially available HemosIL D Dimer Hs kit, which is an enhanced latex immunoassay,

131 and has a sensitivity of 95% and a specificity of 53% on the ACL TOP 500 CTS Coagulation  
132 analyser (Instrumentation Lab, USA). The turnaround time was 15 minutes, and the method  
133 is automated, with the only disadvantage being moderate specificity. [9] Patients who had  
134 CVST were subjected to further workup for the aetiology of CVST and were counselled  
135 regarding the nature of their disease.

## 136 **Statistical analysis**

137 Demographic information was collected in a predetermined checklist. Sample size  
138 calculation was done using the Buderer formula (10) and a total of 83 participants were  
139 enrolled into the study. Categorical data was represented as n (%), Continuous data was  
140 presented as its mean and standard deviation or in the form of its median and interquartile  
141 range as per the normality of data. Chi-square/Fischer's test was applied for comparison of  
142 the categorical variables as appropriate. Binary logistic regression was used to test the  
143 significance between D Dimer values and Positive/negative Cases of CVST. ROC analysis and  
144 area under the curve (AUC) was computed to determine the optimum cut-off value for  
145 exclusion of CVST. All the comparisons were at a 5% significance level, i.e.,  $p < 0.05$ , was  
146 considered significant. Data was electronically entered using a digital spreadsheet by  
147 MICROSOFT EXCEL (version 16.49). Analysis of data was performed by using IBM SPSS  
148 STATISTICS (version 22.0)

149

150

151

## 152 Results

153 83 participants were enrolled in the study, of which most were females (n=47, 56%). 49  
154 participants were diagnosed with CVST (positive cases) while 34 did not have any  
155 demonstrable thrombus on radiology (negative cases). Female participants constituted the  
156 higher proportion of CVST positive cases (65.3%, P=0.055).

157 A significantly larger number of patients with CVST complained of headaches as compared  
158 to those without CVST. (83.6% vs 52.9%, P=0.002). The presence of visual disturbances  
159 (24.5% vs 17.6%), seizures (55 % vs 50 %) and altered mental status (70% vs 20%) was also  
160 more in patients with CVST as compared to those without CVST, however, the difference  
161 between the two groups was not statistically significant. Among 49 patients of CVST,  
162 24(48.9%) patients had no identifiable risk factor for CVST. Out of the remaining 25  
163 participants, postpartum state (16%), hyperhomocysteinemia (10%) and presence of a  
164 connective tissue disease (6%) were common identifiable risk factors.

165 Patients with CVST had a higher level of quantitative D Dimer than those in the non CVST  
166 group, and this difference was statistically significant. (876.27 ng/mL, IQR 486-1642 vs 538.5  
167 ng/mL, IQR 327-775, P=0.003). The Box-and-Whisker plot (Fig 1) depicts the distribution of  
168 Quantitative D-dimer (ng/mL). The middle horizontal line represents the median  
169 Quantitative D- dimer (ng/mL), the upper and lower bounds of the box represent the 75th  
170 and the 25th centile of Quantitative D-dimer (ng/mL), respectively, and the upper and lower  
171 extent of the whiskers represent the range of Quantitative D-dimer (ng/mL) in each of the  
172 groups.



173

174 **Fig 1. Distribution of Quantitative D Dimer levels in study participants.**

175

176 ROC analysis was carried out to determine the diagnostic performance of Quantitative D-  
177 Dimer assay in Predicting CVST. With an AUROC of 0.694, quantitative D-Dimer Assay has a  
178 poor diagnostic performance in differentiating CVST from non-CVST patients. At a D-Dimer  
179 value of  $\geq 792$  ng/mL, the diagnosis of CVST was likely with a specificity of 79% and a  
180 sensitivity of 57%, however, at a value of  $< 300$  ng/mL, D-Dimer had a sensitivity of 89.8% for  
181 the exclusion of the diagnosis of CVST. (Fig 2), (Table 1)

182

183 **Fig 2 : ROC curve analysis showing diagnostic performance of quantitative D- dimer**  
184 **(ng/mL) in predicting CVST (n = 83)**

185

186 **Table 1: ROC curve analysis showing diagnostic performance of quantitative D- dimer**  
187 **(ng/mL) in predicting CVST (n = 83)**

Parameter	Value (95% CI)
Cutoff (p value)	$\geq 792$ (0.003)
AUROC	0.694 (0.58 - 0.809)
Sensitivity	57.1% (42-71)
Specificity	79.4% (62-91)
Positive Predictive Value	80.0% (63-92)
Negative Predictive Value	56.2% (41-71)
Diagnostic Accuracy	66.3% (55-76)
Positive Likelihood Ratio	2.78 (1.37-5.61)
Negative Likelihood Ratio	0.54 (0.37-0.78)
Diagnostic Odds Ratio	5.14 (1.88-14.06)

188

189 To devise a clinical decision rule, patient factors which had a strongest association with CVST  
190 were identified. After univariate analysis of the data, presence of headache and a D-Dimer  
191 level of  $\geq 792$  ng/mL were significantly associated with the presence of CVST. Other than the  
192 above two, Female gender was also included in the computation of the decision rule as  
193 most of the studies from the recent past have demonstrated that female gender confers a  
194 higher relative risk for the development of CVST. [1, 11, 12, 13].

195 A regression analysis for the diagnosis of CVST was conducted, with the dependent variable  
196 being CVST using all the above mentioned three factors. Multivariate logistic regression was  
197 carried out to identify the odds ratio for all the factors. Following table (Table 2) summarizes  
198 the regression analysis for the dependent variable, CVST, using all the predictor variables  
199 together in one go. The 'OR (univariable)' column lists the odds ratios for each of the  
200 variables with respect to the dependent variable, when these variables are used as single  
201 predictors of the dependent variable, without entering the rest of the variables in the  
202 model. The 'OR (multivariable)' column lists the odds ratios for all the variables when they  
203 are entered in the model together (and are now thus controlling for each other). The first  
204 category in each of the categorical variables is the reference category, against which the  
205 odds ratios of the rest of the variables is calculated.

206

207

208

209 **Table 2: Regression analysis with all variables in the model:**

Dependent: CVST		Absent	Present	OR (univariable)	OR (multivariable)
Gender	Male	19 (52.8)	17 (47.2)	-	-
	Female	15 (31.9)	32 (68.1)	2.38 (0.98-5.95, p=0.058)	2.02 (0.73-5.76, p=0.180)
Headache	Absent	16 (66.7)	8 (33.3)	-	-
	Present	18 (30.5)	41 (69.5)	4.56 (1.70-13.11, p=0.003)	7.47 (2.30-30.04, p=0.002)
D_Dimer	<792	27 (55.1)	22 (44.9)	-	-
	≥792	7 (20.6)	27 (79.4)	4.73 (1.80-13.71, p=0.002)	7.15 (2.29-27.83, p=0.002)
<b>MODEL FIT: <math>\chi^2(3) = 24.74</math>, <math>p = &lt;0.001</math> Pseudo-R<sup>2</sup> = 0.22</b> <b>Number in dataframe = 83, Number in model = 83, Missing = 0</b> <b>AIC = 95.6, C-statistic = 0.809, H&amp;L = Chi-sq(8) NaN (p=NaN)</b>					

210

211 If weightages are assigned to the individual factors by rounding off the odds ratio to the  
 212 nearest integer, Female gender is assigned a score of 2, Headache (if present) is assigned a  
 213 score of 7 and a D-Dimer level of ≥792 ng/mL is assigned a score of 7, with a maximum score  
 214 possible being 16. (Table 3)

215 **Table 3 : Proposed score for the bedside prediction of CVST:**

Patient factor	Score Assigned
Female gender	2
Headache (if present)	7
D-Dimer level ≥ 792 ng/mL	7

216

217 The total score for each participant was calculated and internally validated by ROC analysis  
218 (Fig 3), (Table 4). At a cutoff of Score  $\geq 9$ , the proposed score has good diagnostic accuracy for  
219 CVST (AUROC = 0.809). The odds ratio (95% CI) for the presence of CVST when Score is  $\geq 9$  was  
220 24.75 (3.13-195.81). The relative risk (95% CI) for the presence of CVST when Score is  $\geq 9$  was  
221 2.08 (1.56-2.83).

222

223 **Fig 03: ROC curve analysis showing diagnostic performance of score in predicting CVST**

224 **in suspected patients (n = 83)**

225

226 **Table 4 : ROC curve analysis showing diagnostic performance of score in predicting CVST in**

227 **suspected patients (n = 83)**

Parameter	Value (95% CI)
Cutoff (p value)	$\geq 9$ (<0.001)
AUROC	0.809 (0.72 – 0.897)
Sensitivity	79.6% (66 – 90)
Specificity	67.6% (49 – 83)
Positive predictive value	78% (64 – 88)
Negative predictive value	69.7% (51 – 84)
Diagnostic accuracy	74.4% (64 – 84)
Positive likelihood ratio	2.46 (1.48 – 4.08)
Negative likelihood ratio	0.3 (0.17 – 0.55)
Diagnostic odds ratio	8.15 (3 – 22.5)

228

229

230

231 **Discussion:**

232 A total of 83 patients suspected to be having CVST were enrolled. Forty-nine of the study  
233 participants had radiologically confirmed CVST, and 34 registered participants did not have  
234 CVST. The most common age group for CVST patients is 21 to 30 years (43%). India's largest  
235 hospital-based cohort by Narayan et al. found a mean age of presentation is 31.3 years (8),  
236 and a recent study by J Kalita et al. in 2020, the median age was 28 years. (14) The landmark  
237 ISCVT cohort demonstrated that the median age for patients with CVST is 37 years. (12) All  
238 these studies highlight that the younger age group (21-40yrs) has a higher propensity for the  
239 development of CVST as in the present study.

240 Of all the patients who had CVST, two-third were females. The ISCVT cohort by Ferro et al.  
241 had nearly 75 % females in their study population (12) Though this is a known fact, the risk  
242 factors traditionally associated with CVST are seen in females, limited observational studies  
243 from India have shown an increased number of male patients with CVST. The study by Pai et  
244 al. had 57% of the study participants as males (15), while Narayan et al. had 53 % of their  
245 study population as males. (8) A recent study by Kalita et al. had 52% males in their study.  
246 (14) Most of these studies were hospital-based with a limited number of patients. Another  
247 reason could be a gender bias with a hospital seeking behaviour in males, as evident from  
248 the 2019-2020 census of a tertiary care centre in northern India. (16)

249 Though not statistically significant, the presence of Obesity (20%) and diabetes mellitus  
250 (14%) were more common in patients with CVST than those without CVST. Significant  
251 dehydration and fluid losses in the presence of hyperglycaemic emergencies such as  
252 diabetic ketoacidosis, hyperglycaemic non ketotic coma causes a relatively procoagulant  
253 state which may explain these findings. (17) The study by Pomp et al. in 2007 showed that

254 obesity increases the risk of venous thromboembolism. (18) Obesity also increase the odds  
255 of a person developing CVST in the presence of an underlying procoagulant state. (13)

256 Approximately 83% of patients with CVST reported headache as a symptom on  
257 presentation. Narayan et al. reported headaches in 88 % of CVST patients (8), and Pai et al.  
258 had a headache in 62 % of theirs. (15) Nearly 89 % of patients had a headache in the study  
259 by Ferro et al. (12). Headache is multifactorial and is postulated to be due to stretching of  
260 walls of the Dural sinuses secondary to venous congestion. Hemorrhagic conversion of the  
261 lesion and the subsequent meningeal irritation and raised intracranial pressure may be a  
262 contributing factor. (1) In the Index study, 30% of enrolled CVST patients had papilledema,  
263 while 25 % had visual disturbance. The study by Ferro et al. had a similar percentage  
264 (30%)(12), while analysis by Pai et al. (15) and Narayan et al. (8) had 63 % and 64 % of CVST  
265 patients with papilledema, respectively. Papilledema in CVST is due to raised intracranial  
266 tension, and visual disturbances are a very late sign in papilledema as most of the damage  
267 to the retina in raised ICT occurs at the peripheral neurons, preserving the optic disk and  
268 macula until late in the course of illness. (20) The present study had 55% of CVST patients  
269 with seizure episodes on presentation, while other studies from India have fewer (30%,40%)  
270 of the CVST patients with this manifestation. (8), (15) Presence of seizures was commonly  
271 seen in postpartum CVST. (1), (12), (21). Motor deficits were more in the patients without  
272 CVST than those with CVST.(23% vs 20 %). This was probably due to the fact that more  
273 patients had an arterial stroke in the Non-CVST group, moreover, motor deficits that are  
274 readily discernible depend on the motor cortex being involved, which may not always be the  
275 case with CVST due to overlapping cerebral involvement involving multiple arterial

276 territories. Hemiparesis noted in 50 % of CVST patients by Pai et al. (15), while Narayan et  
277 al.(8) and Ferro et al.(12) reported motor deficit in 28% and 37% CVST patients, respectively.

278 Patients with CVST, even those with known procoagulant states, were investigated for the  
279 presence of any new condition that could precipitate CVST. In the ISCVT cohort study of  
280 CVST patients, 13% did not have any identifiable risk factor. (12) In contrast, the present  
281 study found that 48% of CVST cases had no identifiable risk factor. Referral bias or lack of  
282 thorough workup due to the COVID pandemic may have contributed to higher proportion  
283 Idiopathic CVST cases in the present study. Postpartum state (16%) was the most common  
284 risk factor for CVST in this study, while Narayan et al.(8) and Pai et al.(15) identified 10% and  
285 3 % of postpartum CVST cases, respectively. Other identifiable risk factors in this study was  
286 hyperhomocysteinemia (10%), followed by connective tissue disease (6%), OCP intake (4 %)  
287 and dehydration (4%). In a minority of patients, CNS infections, APLA, Protein S deficiency,  
288 malignancy, systemic Vasculitis were also identified. Two patients who were admitted with  
289 severe COVID 19 infection were enrolled in this study but then were later excluded as the  
290 disease duration was more than a week in these patients. None of the patients with CVST  
291 were COVID 19 vaccine recipients, the last patient enrolled in the study was at the time  
292 when the public vaccination programme was in its initial stages.

293 D Dimer is a fibrin degradation product, and though its presence in an elevated amount  
294 does not provide a host of information, low levels of D-Dimer aids in the exclusion of certain  
295 thrombotic disorders such as Deep vein thrombosis and pulmonary thromboembolism  
296 owing to its high negative predictive value. This idea was extrapolated and an attempt was  
297 made to evaluate the sensitivity of D-Dimer in exclusion of CVST patients in this study. (22)  
298 Role of D-Dimer in the diagnosis or exclusion of cerebral venous thrombosis is debatable,

299 with the major limitation of the test being its non-specific nature, frequently leading to  
300 detection of elevated levels even in patients who did not have CVST. Most of the studies  
301 conducted in the past have demonstrated some utility of D-Dimer assay in exclusion of CVST  
302 in low risk patients who present with a headache, however, such a finding is often  
303 compounded by the fact that these patients will usually have another concomitant  
304 pathology which can contribute to the elevated D-Dimer levels. (23), (24), (25), (26) A Study  
305 by Ran Meng et al. in 2014 has shown the mean level of D Dimer was  $968.9 \pm 160$  ng/mL in  
306 patients with CVST, which was significantly higher than in those without CVST. (27) A study  
307 analysing the utility of D Dimer in CVST patients by Tardy B et al. found that a value of <500  
308 ng/mL was highly sensitive to rule out CVST. (26) Our study found that the median value of  
309 D Dimer was significantly elevated in the patients with CVST compared to those without  
310 CVST. (876 ng/mL vs 538 ng/mL) Further, on ROC analysis, D-dimer found to have low  
311 diagnostic accuracy in differentiating CVST from Non-CVST cases (AUROC 0.694).

312 For the computation of a clinical prediction rule, an initial univariate analysis was conducted  
313 that identified that Headache and an elevated D Dimer were significantly associated with  
314 the presence of CVST. Female gender was also considered for the above model as extensive  
315 studies by Leys D et al. (11), Ferro et al. (12) has clearly shown a significantly higher  
316 association of CVST with the female gender. The odds ratio for each of these three variables  
317 were computed using Multivariate regression analysis, which were rounded off to the  
318 nearest integer and assigned as a 'weightage' (headache 7 points, Female gender 2 points, D  
319 Dimer >792 ng/mL 7 points). This scoring was internally validated in the study population,  
320 and ROC analysis identified the cut-off score of  $\geq 9$ , above which the diagnosis of CVST was  
321 highly likely (AUROC = 0.809). This methodology of generating the clinical prediction model



322 is analogous to the 2020 study by Heldner et al., which demonstrated that the addition of D  
323 Dimer as a component in the clinical scoring improved the overall diagnostic accuracy of the  
324 score (AUROC 0.889 without D Dimer to AUROC 0.937 with the inclusion of D Dimer). (29)

325

## 326 **Conclusions**

- 327 1. ROC analysis revealed that D-Dimer assay had a poor diagnostic accuracy in  
328 differentiating CVST from non-CVST patients (AUROC = 0.694), however, a D-Dimer  
329 level of <300 ng/mL had a sensitivity of 90% to exclude the diagnosis of CVST.
- 330 2. After logistic regression analysis, a clinical decision rule with a total score of 16 and  
331 individual components of Female gender (2 points), Presence of headache (7 points),  
332 presence of D-Dimer levels of  $\geq 792$  ng/mL (7 points) was devised, a score of  $\geq 9$  had  
333 good diagnostic accuracy for the prediction of CVST. (AUROC = 0.809)

334

## 335 **Limitations of the study**

- 336 1. The study was conducted at a single centre, since referral bias may be a factor in  
337 such a centre, it may not be representative of the entire population. Multicentre  
338 studies would be ideal for a study with such a goal.
- 339 2. The sample size was limited to 83 patients, inclusion of a larger number of  
340 participants in future studies is needed for the information obtained to be  
341 generalizable.

- 342 3. The study period was for 17 months and follow up of the enrolled participants could  
343 not be carried out
- 344 4. Patient's genetic factors as well as the presence of infections, inflammatory response  
345 of the body, co-administered drugs can interfere with the measurement of  
346 quantitative D-Dimer assay, though any clinically possible interference with the  
347 results was thought of, given the logistical and resource constrains, it is difficult to  
348 exclude all the factors that may lead to altered levels of D-Dimer.
- 349 5. In the computation of clinical decision rule, the presence of Female gender was  
350 taken as a component of the decision rule, in our study, however, the presence of  
351 female gender was not significantly associated with the presence of CVST with the p  
352 value just approaching the cut off of 0.05. (actual p = 0.055)
- 353 6. The proposed clinical decision rule is internally validated in the study and needs to  
354 be externally validated in subsequent studies to standardise the findings.

355

## 356 **Acknowledgements**

357 The authors would like to acknowledge the help provided by the coagulation laboratory staff,  
358 Mr. Chanderhans and Ms. Anita Kler. We would also like to extend our gratitude to Junior  
359 administrative assistant, Mr. Ajay Kumar for his input in statistical analysis.


360

## 361 **References**


- 362 1. Dash D, Prasad K, Joseph L. Cerebral venous thrombosis: An Indian perspective.  
363 Neurol India. 2015;63(3):318–28.
- 364 2. Ferro JM, Canhão P. Cerebral venous sinus thrombosis: update on diagnosis and  
365 management. Curr Cardiol Rep. 2014;16(9):523.
- 366 3. Bansal BC, Gupta RR, Prakash C. Stroke during pregnancy and puerperium in young  
367 females below the age of 40 years as a result of cerebral venous/venous sinus  
368 thrombosis. Jpn Heart J 1980;21:171-73
- 369 4. Banerjee AK, Varma M, Vasista RK, Chopra JS. Cerebrovascular disease in north-west  
370 India: A study of necropsy material. J Neurol Neurosurg Psychiatry 1989;52:512-5
- 371 5. Stam J. Thrombosis of the cerebral veins and sinuses. N Engl J Med 2005; 352: 1791-  
372 8
- 373 6. Chiewvit P, Piyapittayanan S, Pongvarin N. Cerebral venous thrombosis: diagnosis  
374 dilemma. Neurol Int. 2011;3(3):13
- 375 7. Cucchiara B, Messe S, Taylor R, Clarke J, Pollak E. Utility of D-dimer in the diagnosis  
376 of cerebral venous sinus thrombosis. J Thromb Haemost 2005; 3: 387–9
- 377 8. Narayan D, Kaul S, Ravishankar K, Suryaprabha T, Bandaru VCSS, Mridula KR, et al.  
378 Risk factors, clinical profile, and long-term outcome of 428 patients of cerebral sinus  
379 venous thrombosis. Neurol India. 2012 Mar-Apr;60(2):154-9
- 380 9. Linkins L, Lapner ST. Review of D- dimer testing : Good , Bad , and Ugly. Int J Lab  
381 Hematol. 2017 May;39 Suppl 1:98-103
- 382 10. Fenn Buderer NM. Statistical methodology: incorporating the prevalence of disease  
383 into the sample size calculation for sensitivity and specificity. Acad Emerg Med.  
384 1996;3(9):895–900.

- 385 11. Leys D, Cordonnier C. Cerebral venous thrombosis: Update on clinical  
386 manifestations, diagnosis and management. *Ann Indian Acad Neurol.* 2008;11.
- 387 12. Ferro JM, Canhão P, Stam J, Bousser MG, Barinagarrementeria F. Prognosis of  
388 Cerebral Vein and Dural Sinus Thrombosis: Results of the International Study on  
389 Cerebral Vein and Dural Sinus Thrombosis (ISCVT). *Stroke.* 2004;35(3):664–70.
- 390 13. Zuurbier SM, Arnold M, Middeldorp S, Broeg-Morvay A, Silvis SM, Heldner MR, et al.  
391 Risk of Cerebral Venous Thrombosis in Obese Women. *JAMA Neurol.* 2016 May  
392 1;73(5):579-84
- 393 14. Kalita J, Singh VK, Misra UK. A study of hyperhomocysteinemia in cerebral venous  
394 thrombosis. *Indian J Med Res* 2020; 152:584-94.
- 395 15. Pai N, Ghosh K, Shetty S. Hereditary thrombophilia in cerebral venous thrombosis: A  
396 study from India. *Blood Coagul Fibrinolysis.* 2013;24(5):540–3.
- 397 16. Sahni D et al. 2020. 53<sup>rd</sup> Annual Report, PGIMER.
- 398 17. Keane S, Gallagher A, Ackroyd S, et al Cerebral venous thrombosis during diabetic  
399 ketoacidosis *Archives of Disease in Childhood* 2002;86:204-205
- 400 18. Pomp ER, le Cessie S, Rosendaal FR, Doggen CJ. Risk of venous thrombosis: obesity  
401 and its joint effect with oral contraceptive use and prothrombotic mutations. *Br J*  
402 *Haematol.* 2007;139 (2):289-29
- 403 19. Ferro JM, Aguiar de Sousa D. Cerebral Venous Thrombosis: an Update. *Curr Neurol*  
404 *Neurosci Rep.* 2019 Aug 23;19(10):74.
- 405 20. Wall M, George D. Visual Loss in Pseudotumor Cerebri: Incidence and Defects  
406 Related to Visual Field Strategy. *Arch Neurol.* 1987;44(2):170–175
- 407 a. Ferro JM, Bousser MG, Canhão P, Coutinho JM, Crassard I, Dentali F, et al.  
408 European Stroke Organization guideline for the diagnosis and treatment of


- 409 cerebral venous thrombosis Endorsed by the European Academy of Neurology.  
410 Eur Stroke J. 2017;2(3):195–221.
- 411 21. Couturaud F, Kearon C, Bates SM, Ginsberg JS. Decrease in sensitivity of D-dimer for  
412 acute venous thromboembolism after starting anticoagulant therapy. Blood Coagul  
413 Fibrinolysis. 2002 Apr;13(3):241-6
- 414 22. Caplan LR. Caplan’s Stroke. 5<sup>th</sup> edition. United Kingdom: Cambridge University Press;  
415 2016
- 416 23. Fernandes CJ, Morinaga LTK, Alves JL Jr, Castro MA, Calderaro D, Jardim CVP, Souza  
417 R. Cancer- associated thrombosis: the when, how and why. Eur Respir Rev. 2019 Mar  
418 27;28(151):180119
- 419 24. Alons IME, Jellema K, Wermer MJH, Algra A. D DIMER for the exclusion of cerebral  
420 venous thrombosis: A meta-analysis of low risk patients with isolated headache.  
421 BMC Neurol. 2015;15(1):1–7.
- 422 25. Smith, E., & Kumar, V. (2018). BET 1: Does a normal D-dimer rule out cerebral venous  
423 sinus thrombosis (CVST). Emergency Medicine Journal. 2018
- 424 26. Meng R, Wang X, Hussain M, Dornbos D 3rd, Meng L, Liu Y, Wu Y, Ning M,  
425 Ferdinando S B, Lo EH, Ding Y, Ji X. Evaluation of plasma D-dimer plus fibrinogen in  
426 predicting acute CVST. Int J Stroke. 2014 Feb;9(2):166-73.
- 427 27. Tardy B, et al. D-Dimer levels in patients with suspected acute cerebral venous  
428 thrombosis. Am j Med. 2002;113:238-241
- 429 28. Heldner MR, Zuurbier SM, Li B, Von Martial R, Meijers JCM, Zimmermann R, Volbers  
430 B, Jung S, El-Koussy M, Fischer U, Kohler HP, Schroeder V, Coutinho JM, Arnold M.  
431 Prediction of cerebral venous thrombosis with a new clinical score and D-dimer  
432 levels. Neurology. 2020 Aug 18;95(7):e898-e909



Distribution of quantitative D-Dimer levels amongst study participants



ROC curve analysis showing diagnostic performance of quantitative



ROC curve analysis showing diagnostic performance of score in p